F-18 FDG perfusion PET: intraprocedural assessment of the liver tumor ablation margin

Shyn, Paul B.; Cubre, Alan; Catalano, Paul J.; Lee, Leslie K.; Hyun, Hyewon; Tuncalı, Kemal; Seol, Julia G.; Levesque, Vincent M.; Gerbaudo, Victor H.; Kapur, Tina; Chao, Ryan T; Silverman, Stuart G.

doi:10.1007/s00261-021-02970-8

Cited by 11 publications

(3 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The intraprocedural 3D assessment of volumes of insufficient coverage by a 5 mm margin exhibited a higher AUC compared to the 4-8-week post-ablation CE-CT for predicting local tumor progression after a median follow-up of 19.6 months (AUC: 0.78 vs. 0.67) [70]. Furthermore, the addition of intraprocedural FDG PET/CT to CE-CT has also been demonstrated by both retrospective and prospective studies to improve targeting accuracy and enable precise endpoint evaluation after TA [10,[71][72][73][74]. A recent study by Zirakchian Zadeh et al with 190 CLMs from 125 patients showed that only 4 (2.1%) CRLMs remained undetected or had poor avidity on intraprocedural PET/CT, while CT alone could not reliably establish the minimal ablation margins in 61 (32.1%) of the cases, highlighting its potential for effective ablation targeting [72].…”

Section: Image-guided Percutaneous Ablationmentioning

confidence: 95%

Imaging Considerations before and after Liver-Directed Locoregional Treatments for Metastatic Colorectal Cancer

Chlorogiannis,

Moussa,

Zhao

et al. 2024

Diagnostics

View full text Add to dashboard Cite

Colorectal cancer is a leading cause of cancer-related death. Liver metastases will develop in over one-third of patients with colorectal cancer and are a major cause of morbidity and mortality. Even though surgical resection has been considered the mainstay of treatment, only approximately 20% of the patients are surgical candidates. Liver-directed locoregional therapies such as thermal ablation, Yttrium-90 transarterial radioembolization, and stereotactic body radiation therapy are pivotal in managing colorectal liver metastatic disease. Comprehensive pre- and post-intervention imaging, encompassing both anatomic and metabolic assessments, is invaluable for precise treatment planning, staging, treatment response assessment, and the prompt identification of local or distant tumor progression. This review outlines the value of imaging for colorectal liver metastatic disease and offers insights into imaging follow-up after locoregional liver-directed therapy.

show abstract

Section: Image-guided Percutaneous Ablationmentioning

confidence: 95%

Imaging Considerations before and after Liver-Directed Locoregional Treatments for Metastatic Colorectal Cancer

Chlorogiannis,

Moussa,

Zhao

et al. 2024

Diagnostics

View full text Add to dashboard Cite

show abstract

“…In addition, the use of immediate fluorescent stains on ablation zone tissue can detect necrotic versus residual viable tumor intra-procedurally and can predict LTP at 12 months [ 153 ]. Similarly, real-time metabolic imaging has been used as a surrogate imaging biomarker of residual disease after ablation and is predictive of LTP [ 154 , 155 , 156 , 157 , 158 , 159 ].…”

Section: Biomarkers and Interventional Oncology For Crlmmentioning

confidence: 99%

Colorectal Cancer Liver Metastases: Genomics and Biomarkers with Focus on Local Therapies

Kitsel

Cooke

Sotirchos

et al. 2023

Cancers

View full text Add to dashboard Cite

Molecular cancer biomarkers help personalize treatment, predict oncologic outcomes, and identify patients who can benefit from specific targeted therapies. Colorectal cancer (CRC) is the third-most common cancer, with the liver being the most frequent visceral metastatic site. KRAS, NRAS, BRAF V600E Mutations, DNA Mismatch Repair Deficiency/Microsatellite Instability Status, HER2 Amplification, and NTRK Fusions are NCCN approved and actionable molecular biomarkers for colorectal cancer. Additional biomarkers are also described and can be helpful in different image-guided hepatic directed therapies specifically for CRLM. For example, tumors maintaining the Ki-67 proliferation marker after thermal ablation was shown to be particularly resilient to ablation. Ablation margin was also shown to be an important factor in predicting local recurrence, with a ≥10 mm minimal ablation margin being required to attain local tumor control, especially for patients with mutant KRAS CRLM.

show abstract

“…Another emerging PET technique is combined metabolic and perfusion. This method has not been used in HIFU ablation as yet, but the combination of 18 F-FDG [ 120 ] and 13 N-ammonia [ 22 ] during intraprocedure PET has been explored in liver thermal ablation using microwaves with good results in defining ablation margins. Additionally, 15 O-water has been evaluated to directly track the behavior of water during repeated thermal dose administrations [ 121 ].…”

Section: Positron Emission Tomographymentioning

confidence: 99%

A Review of Imaging Methods to Assess Ultrasound-Mediated Ablation

et al. 2022

View full text Add to dashboard Cite

Ultrasound ablation techniques are minimally invasive alternatives to surgical resection and have rapidly increased in use. The response of tissue to HIFU ablation differs based on the relative contributions of thermal and mechanical effects, which can be varied to achieve optimal ablation parameters for a given tissue type and location. In tumor ablation, similar to surgical resection, it is desirable to include a safety margin of ablated tissue around the entirety of the tumor. A factor in optimizing ablative techniques is minimizing the recurrence rate, which can be due to incomplete ablation of the target tissue. Further, combining focal ablation with immunotherapy is likely to be key for effective treatment of metastatic cancer, and therefore characterizing the impact of ablation on the tumor microenvironment will be important. Thus, visualization and quantification of the extent of ablation is an integral component of ablative procedures. The aim of this review article is to describe the radiological findings after ultrasound ablation across multiple imaging modalities. This review presents readers with a general overview of the current and emerging imaging methods to assess the efficacy of ultrasound ablative treatments.

show abstract

F-18 FDG perfusion PET: intraprocedural assessment of the liver tumor ablation margin

Cited by 11 publications

References 23 publications

Imaging Considerations before and after Liver-Directed Locoregional Treatments for Metastatic Colorectal Cancer

Imaging Considerations before and after Liver-Directed Locoregional Treatments for Metastatic Colorectal Cancer

Colorectal Cancer Liver Metastases: Genomics and Biomarkers with Focus on Local Therapies

A Review of Imaging Methods to Assess Ultrasound-Mediated Ablation

Contact Info

Product

Resources

About